Animal models of human cardiovascular disease, heart failure and hypertrophy

Cardiovascular Research

Volumn 39, Issue 1, 1998, Pages 60-76

  Hasenfuss, Gerd ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Animal models; Calcium; Heart failure; Hypertrophy

Indexed keywords

CARDIOVASCULAR DISEASE; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; MODEL; MOLECULAR BIOLOGY; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOMEGALY; CARDIOVASCULAR DISEASES; CATS; CATTLE; CRICETINAE; DISEASE MODELS, ANIMAL; DOGS; GUINEA PIGS; HEART FAILURE, CONGESTIVE; HUMANS; MESOCRICETUS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SHEEP; SWINE; TURKEYS;

EID: 0032126258     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00110-2     Document Type: Review

References (224)

1. [1] Yamani M, Massie BM. Congestive heart failure: insights from epidemiology, implications for treatment. Mayo Clin Proc 1993;68:1214-1218.
2. [2] Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-115.
3. [3] The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
4. [4] Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
5. [5] The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
6. [6] Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma-renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(Suppl VI):40-48.
7. [7] Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-711.
8. [8] Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depresses left ventricular ejection fraction: a report from the study of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206.
9. [9] Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997;95:169-175.
10. [10] Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;3:1667-1676.
11. [11] Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995;92:3206-3211.
12. [12] Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-1729.
13. [13] Shan K, Kurrelmeyer K, Seta Y, et al. The role of cytokines in disease progression in heart failure. Curr Opin Cardiol 1997;12:218-223.
14. [14] Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-641.
15. [15] Katz SD. Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol 1997;12:259-264.
16. [16] Wroblewski H, Sindrup JH, Norgaard T, Haunso S, Kastrup J. Effects of orthotopic cardiac transplantation on structural microangiopathy and abnormal hemodynamics in idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:281-285.
17. [17] Katz SD, Krum H, Khan T, Knecht M. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 1996;28:585-590.
18. [18] Hasenfuss G, Mulieri LA, Leavitt BJ, et al. Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy. Circ Res 1992;70:1225-1232.
19. [19] Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992;85:1046-1055.
20. [20] Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987;61:70-76.
21. [21] Pieske B, Kretschmann B, Meyer M, et al. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 1995;92:1169-1178.
22. [22] Hasenfuss G, Holubarsch C, Hermann HP, et al. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Europ Heart J 1994;15:164-170.
23. 2+ handling. J Clin Invest 1996;98:764-776.
24. [24] Piot C, Lemaire S, Albat B. High frequency-induced upregulation of human cardiac calcium currents. Circulation 1996;93:120-128.
25. [25] Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 1998;37:279-289.
26. [26] Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96:2178-2182.
27. [27] Ginsburg R, Bristow MR, Billingham ME, et al. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J 1983;106:535-540.
28. [28] Feldman MD, Copelas L, Gwathmey JK, et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987;75:331-339.
29. [29] Alpert NR, Gordon MS. Myofibrillar adenosine triphosphatase activity in congestive heart failure. Am J Physiol 1962;202:940-946.
30. [30] Mercadier JJ, Bouveret P, Gorza L, et al. Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circ Res 1983;53:52-62.
31. [31] Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy-chain gene expression in human heart failure. J Clin Invest 1997;100:2362-2370.
32. [32] Lowes BD, Minobe W, Abraham WT, et al. Changes in gene expression in the intact human heart. Downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997;100:2315-2324.
33. [33] Anderson PA, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 1991;69:1226-1233.
34. [34] Margossian SS, White HD, Caulfield JB, et al. Light chain 2 profile and activity of human ventricular myosin during dilated cardiomyopathy. Identification of a causal agent for impaired myocardial function. Circulation 1992;85:1720-1733.
35. 2+ in intact and skinned trabeculae from control and myopathic human hearts. J Clin Invest 1988;82:1578-1584.
36. 2+ release activity of the sarcoplasmic reticulum in dilated cardiomyopathy. Circulation 1992;85:518-525.
37. [37] Schwinger RH, Bohm M, Koch A, et al. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res 1994;74:959-969.
38. [38] Wolff MR, Buck SH, Stoker SW, Greaser ML, Mentzer RM. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation. J Clin Invest 1996;98:167-176.
39. [39] Bristow MR, Minobe WA, Raynolds MV, et al. Reduced beta-1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 1993;92:2737-2745.
40. [40] Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta1-adrenergic receptors in the failing human heart. Circulation 1993;87:454-463.
41. [41] Brodde OE, Michel MC, Zerkowski HR. Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Cardiovasc Res 1995;30:570-584.
42. [42] Marijianowski MMH, Teeling P, Mann J, Becker AE. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 1995;25:1263-1272.
43. [43] Schaper J, Froede R, Hein S, et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 1991;83:504-514.
44. [44] Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-512.
45. [45] Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-355.
46. [46] Bers DM. Control of cardiac contraction by SR-Ca release and sarcolemmal-Ca fluxes. In: Bers DM, editor. Excitation-contraction coupling and cardiac contractile force. Developments in cardiovascular medicine, vol. 122. Dordrecht, Boston, London: Kluver Academic Publishers, 1991:149-170.
47. 2+-content in myocardium from patients with heart failure. Circulation 1997;96(Suppl I):199.
48. [48] Swynghedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol Rev 1986;66:710-771.
49. [49] Kajstura J, Zhang X, Reiss K, et al. Myocyte cellular hyperplasia and myocyte cellular hypertrophy contribute to chronic ventricular remodeling in coronary artery narrowing-induced cardiomyopathy in rats. Circ Res 1994;74:383-400.
50. [50] Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994;89:345-354.
51. [51] van Veldhuisen DJ, van Gilst WH, de Smet BJ, et al. Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure. Cardiovasc Drugs Ther 1994;8:245-250.
52. [52] Hodsman GP, Kohzuki M, Howes LG, et al. Neurohumoral responses to chronic myocardial infarction in rats. Circulation 1988;78:376-381.
53. [53] Teerlink JR, Loffler BM, Hess P, et al. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor-antagonist Ro 47-0203 (Bosentan). Circulation 1994;90:2510-2518.
54. [54] Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 1993;25:1369-1380.
55. [55] Pinto YM, de Smet BG, van Gilst WH, et al. Selective and time-related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 1993;27:1933-1938.
56. [56] Litwin SE, Morgan JP. Captopril enhances intracellular calcium handling and beta-adrenergic responsiveness of myocardium from rats with postinfarction failure. Circ Res 1992;71:797-807.
57. [57] Dixon IM, Lee SL, Dhalla NS. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ Res 1990;66:782-788.
58. 2+ channels in experimental cardiac failure. Am J Physiol 1991;261:H1979-H1987.
59. 2+-pump ATPase in congestive heart failure due to myocardial infarction. Mol Cell Biochem 1996;163-164:285-290.
60. [60] Liu YH, Yang XP, Nass O, et al. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol 1997;272:H722-727.
61. 2+-ATPase in cardiac hypertrophy by angiotensin converting enzyme?. Basic Res Cardiol 1992;87(Suppl II):191-204.
62. [62] Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 1993;73:184-192.
63. [63] Weinberg EO, Schoen FJ, George D, et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994;90:1410-1422.
64. [64] Schunkert H, Lorell BH. Role of angiotensin II in the transition of left ventricular hypertrophy to cardiac failure. Heart Failure 1994;10:142-149.
65. [65] Elsner D, Riegger GA. Characteristics and clinical relevance of animal models of heart failure. Curr Opin Cardiol 1995;10:253-259.
66. [66] Dahl LK, Heine M, Tassinari L. Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature 1962;194:480-482.
67. [67] Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol 1994;267:H2471-H2482.
68. [68] Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963;27:282-293.
69. [69] Bing OH, Brooks WW, Conrad CH, et al. Intracellular calcium transients in myocardium from spontaneously hypertensive rats during the transition to heart failure. Circ Res 1991;68:1390-1400.
70. [70] Boluyt MO, O'Neill L, Meredith AL, et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circ Res 1994;75:23-32.
71. [71] Li Z, Bing OH, Long X, Robinson KG, Lakatta EG. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol 1997;272:H2313-H2319.
72. [72] Chua Jr. SC, Chung WK, Wu-Peng XS. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996;271:994-996.
73. [73] Holycross BJ, Summers BM, Dunn RB, McCune SA. Plasma-renin activity in heart failure-prone SHHF/Mcc-facp rats. Am J Physiol 1997;273:H228-H233.
74. [74] Narayan P, McCune SA, Robitaille PM, Hohl CM, Altschuld RA. Mechanical alternans and the force-frequency relationship in failing rat hearts. J Mol Cell Cardiol 1995;27:523-530.
75. [75] Gomez AM, Valdivia HH, Cheng H, et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 1997;276:800-806.
76. [76] Khadour FH, Kao RH, Park S, et al. Age-dependent augmentation of cardiac endothelial NOS in a genetic rat model of heart failure. Am J Physiol 1997;273:H1223-H1230.
77. [77] Lompre AM, Mercadier JJ, Wisnewsky C, et al. Species and age-dependent changes in the relative amounts of cardiac myosin isozymes in mammals. Dev Biol 1981;84:286-290.
78. [78] Freeman GL, Little WC, O'Rourke RA. Influence of heart rate on left ventricular performance in conscious dogs. Circ Res 1987;61:455-464.
79. [79] Whipple GH, Sheffield LT, Woodman EG, Thoephilis C, Friedman S. Reversible congestive heart failure due to rapid stimulation of the normal heart. Proc New Eng Cardiovasc Soc 1961;20:39-40.
80. [80] Armstrong PW, Stopps TP, Ford SE, de Bold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 1986;74:1075-1084.
81. [81] Wilson JR, Douglas P, Hickey WF, et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987;75:857-867.
82. [82] Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation 1994;89:2241-2250.
83. [83] Kiuchi K, Shannon RP, Sato N, et al. Factors involved in delaying the rise in peripheral resistance in developing heart failure. Am J Physiol 1994;267:H211-H216.
84. [84] Armstrong PW, Gordon WM. The development of and recovery from pacing-induced heart failure. In: Spinale FG, editor. Pathophysiology of tachycardia-inuced heart failure. Armonk, NY: Futura Publishing Company, 1996;45-59.
85. [85] Eaton GM, Cody RJ, Nunziata E, Binkley PF. Early left ventricular dysfunction elicits activation of sympathetic drive and attenuation of parasympathetic tone in the paced canine model of congestive heart failure. Circulation 1995;92:555-561.
86. [86] Travill CM, Williams TD, Pate P, et al. Haemodynamic and neurohumoral response in heart failure produced by rapid ventricular pacing. Cardiovasc Res 1992;26:783-790.
87. [87] Redfield MM, Aarhus LL, Wright RS, Burnett Jr. JC. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation 1993;87:2016-2022.
88. [88] Luchner A, Stevens TL, Borgeson DD, et al. Angiotensin II in the evolution of experimental heart failure. Hypertension 1996;28:472-477.
89. [89] Wang J, Seyedi N, Xu XB, Wolin MS, Hintze TH. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol 1994;266:H670-H680.
90. [90] Ohno M, Cheng CP, Little WC. Altered left ventricular systolic and diastolic force-frequency relation in heat failure. Circulation 1994;90(Suppl I):112.
91. [91] Cheng CP, Noda T, Nozawa T, Little WC. Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow. Circ Res 1993;72:795-806.
92. [92] Ravens U, Davia K, Davies Ch, et al. Tachycardia-induced failure alters contracile properties of canine ventricular myocytes. Cardovasc Res 1996;32:613-621.
93. [93] Komamura K, Shannon RP, Ihara T, et al. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol 1993;265:H1119-H1131.
94. [94] Perreault CL, Shannon RP, Komamura K, Vatner SF, Morgan JP. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest 1992;89:932-938.
95. [95] Zile MR, Mukherjee R, Clayton C, Kato S, Spinale FG. Effects of chronic supraventricular pacing tachycardia on relaxation rate in isolated cardiac muscle cells. Am J Physiol 1995;268:H2104-H2113.
96. [96] Williams RE, Kass DA, Kawagoe Y, et al. Endomyocardial gene expression during development of pacing tachycardia-induced heart failure in the dog. Circ Res 1994;75:615-623.
97. [97] O'Rourke B, Fan Peng Ling, Tomaselli GF, Marban E. Excitation contraction coupling alterations in canine tachycardia-induced heart failure. Circulation 1997;96(Suppl I):238.
98. 2+ cycle in congestive heart failure produced in dogs by idiopathic dilated cardiomyopathy and rapid ventricular pacing. J Mol Cell Cardiol 1994;26:173-184.
99. [99] Vatner DE, Sato N, Kiuchi K, Shannon RP, Vatner SF. Decrease in myocardial ryanodine receptors and altered excitation-contraction coupling early in the development of heart failure. Circulation 1994;90:1423-1430.
100. [100] Wolff MR, Whitesell LF, Moss RL. Calcium sensitivity of isometric tension is increased in canine experimental heart failure. Circ Res 1995;76:781-789.
101. [101] O'Leary EL, Colston JT, Freeman GL. Maintained length-dependent activation of skinned myocardial fibers in tachycardia heart failure. Circulation 1992;86(suppl I):284.
102. [102] Spinale FG, Holzgrefe HH, Mukherjee R, et al. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function. Circulation 1995;92:562-578.
103. [103] Liu Y, Cigola E, Cheng W, et al. Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest 1995;73:771-787.
104. [104] Ishikawa Y, Sorota S, Kiuchi K, et al. Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J Clin Invest 1994;93:2224-2229.
105. [105] Pak PH, Nuss HB, Kaab S, et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia induced cardiomyopathy. J Am Coll Cardiol 1997;30:576-584.
106. [106] Nuss HB, Johns DC, Kaab S, et al. Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene tranfer: a prototype for gene therapy for disorders of cardiac excitability and contractility. Gene Ther 1996;3:900-912.
107. [107] Spinale FG, Fulbright BM, Mukherjee R, et al. Relation between ventricular and myocyte function with tachycardia-induced cardiomyopathy. Circ Res 1992;71:174-187.
108. [108] Spinale FG, Hendrick DA, Crawford FA, et al. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Phys 1990;259:H218-H229.
109. [109] Spinale FG, Tomita M, Zellner JL, et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 1991;261:H308-H318.
110. [110] Spinale FG, Tempel GE, Mukherjee R, et al. Cellular and molecular alterations in the beta adrenergic system with cardiomyopathy induced by tachycardia. Cardiovasc Res 1994;28:1243-1250.
111. [111] Sabbah HN, Stein PD, Kono T, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260:H1379-H1384.
112. [112] Gengo PJ, Sabbah HN, Steffen RP, et al. Myocardial beta adrenoceptor and voltage-sensitive calcium channel changes in a canine model of chronic heart failure. J Mol Cell Cardiol 1992;24:1361-1369.
113. 2+-ATPase activity and expression in ventricular myocardium of dogs with heart failure. Am J Physiol 1997;273:H12-H18.
114. [114] Sabbah HN, Shimoyama H, Kono T, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-2859.
115. [115] McDonald KM, Francis GS, Carlyle PF, et al. Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog. J Am Coll Cardiol 1992;19:460-467.
116. [116] McCullagh WH, Covell JW, Ross Jr. J. Left ventricular dilatation and diastolic compliance changes during chronic volume overloading. Circulation 1972;45:943-951.
117. [117] Kleaveland JP, Kussmaul WG, Vinciguerra T, Diters R, Carabello BA. Volume overload hypertrophy in a closed-chest model of mitral regurgitation. Am J Physiol 1988;254:H1034-H1041.
118. [118] Dell'Italia LJ. The canine model of mitral regurgitation. Heart Failure 1995;11:208-218.
119. [119] Nagatsu M, Zile MR, Tsutsui H, et al. Native beta-adrenergic support for left ventricular dysfunction in experimental mitral regurgitation normalizes indexes of pump and contractile function. Circulation 1994;89:818-826.
120. [120] Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994;93:2639-2648.
121. [121] Hasenfuss G, Mulieri LA, Blanchard EM, et al. Energetics of isometric force development in control and volume-overload human myocardium. Comparison with animal species. Circ Res 1991;68:836-846.
122. [122] Magid NM, Opio G, Wallerson DC, Young MS, Borer JS. Heart failure due to chronic experimental aortic regurgitation. Am J Physiol 1994;267:H556-H562.
123. [123] Gilson N, el Houda Bouanani N, Corsin A, Crozatier B. Left ventricular function and beta-adrenoceptors in rabbit failing heart. Am J Physiol 1990;258:H634-H641.
124. [124] Ezzaher A, Bouanani NEH, Su JB, Hittinger L, Crozatier B. Increased negative inotropic effect of calcium channel blockers in hypertrophied and failing rabbit hearts. J Pharmacol Exp Ther 1991;257:466-471.
125. [125] Ezzaher A, Boudanani NEH, Crozatier B. Force-frequency relations and response to ryanodine in failing rabbit hearts. Am J Physiol 1992;263:H1710-H1715.
126. 2+-exchanger gene expression in an arrhythmogenic model of nonischemic cardiomyopathy in the rabbit. Circulation 1997;96(Suppl I):8.
127. [127] Freeman GL, Colston JT. Myocardial depression produced by sustained tachycardia in rabbits. Am J Physiol 1992;262:H63-H67.
128. [128] Masaki H, Imaizumi T, Ando S, et al. Production of chronic congestive heart failure by rapid ventricular pacing in the rabbit. Cardiovasc Res 1993;27:828-831.
129. [129] Masaki H, Imaizumi T, Harasawa Y, Takeshita A. Dynamic arterial baroreflex in rabbits with heart failure induced by rapid pacing. Am J Physiol 1994;267:H92-H99.
130. [130] Ryu KH, Tanaka N, Dalton N, et al. Force-frequency relations in the failing rabbit heart and responses to adrenergic stimulation. J Card Fail 1997;3:27-39.
131. [131] Eble DM, Walker JD, Mukherjee R, Samarel AM, Spinale FG. Myosin heavy chain synthesis is increased in a rabbit model of heart failure. Am J Physiol 1997;272:H969-H978.
132. [132] Dodd DA, Atkinson JB, Olson RD, et al. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest 1993;91:1697-1705.
133. [133] Siri FM, Krueger J, Nordin C, Ming Z, Aronson RS. Depressed intracellular calcium transients and contraction in myocytes from hypertrophied and failing guinea pig hearts. Am J Phys 1991;261:H514-H530.
134. 2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ Res 1995;77:759-764.
135. [135] Malhotra A, Siri FM, Aronson R. Cardiac contractile proteins in hypertrophied and failing guinea pig heart. Cardiovasc Res 1992;26:153-161.
136. [136] Bajusz E. Hereditary cardiomyopathy: a new disease model. Am Heart J 1969;7:686-696.
137. [137] Forman R, Parmley WW, Sonnenblick EH. Myocardial contractility in relation to hypertrophy and failure in myopathic Syrian hamsters. J Mol Cell Cardiol 1972;4:203-211.
138. [138] Jasmin G, Proschek L. Hereditary polymyopathy and cardiomyopathy in the Syrian hamster. I. Progression of heart and skeletal muscle lesions in the UM-X7.1 line. Muscle Nerve 1982;5:20-25.
139. [139] Rouleau JL, Chuck LH, Hollosi G, et al. Verapamil preserves myocardial contractility in the hereditary cardiomyopathy of the Syrian hamster. Circ Res 1982;50:405-412.
140. [140] Whitmer JT, Kumar P, Solaro RJ. Calcium transport properties of cardiac sarcoplasmic reticulum from cardiomyopathic Syrian hamsters (BIO 53.58 and 14.6): evidence for a quantitative defect in dilated myopathic hearts not evident in hypertrophic hearts. Circ Res 1988;62:81-85.
141. [141] Finkel MS, Marks ES, Patterson RE, et al. Correlation of changes in cardiac calcium channels with hemodynamics in Syrian hamster cardiomyopathy and heart failure. Life Sci 1987;41:153-159.
142. [142] Wagner JA, Reynolds IJ, Weisman HF, et al. Calcium antagonist receptors in cardiomyopathic hamster: selective increases in heart, muscle, brain. Science 1986;232:515-518.
143. [143] Kuo TH, Tsang W, Wang KK, Carlock L. Simultaneous reduction of the sarcolemmal and SR calcium ATPase activities and gene expression in cardiomyopathic hamster. Biochim Biophys Acta 1992;1138:343-349.
144. 2+ exchange activity in cardiomyopathic Syrian hamster. Circ Res 1994;74:253-261.
145. [145] Malhotra A, Karell M, Scheuer J. Multiple cardiac contractile protein abnormalities in myopathic Syrian hamsters (BIO 53: 58). J Mol Cell Cardiol 1985;17:95-107.
146. [146] Okazaki Y, Okuizumi H, Osumi T, et al. A genetic linkage map of the Syrian hamster and localization of cardiomyopathy locus on chromosome 9qa2.1-b1 using RLGS spot-mapping. Nat Genet 1996;13:87-90.
147. [147] Nigro V, Okazaki Y, Belsito A, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Gen 1997;6:601-607.
148. [148] Hoit BD, Khoury SF, Kranias EG, Ball N, Walsh RA. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res 1995;77:632-637.
149. [149] Rockman HA, Ono S, Ross RS, et al. Molecular and physiological alterations in murine ventricular dysfunction. Proc Natl Acad Sci USA 1994;91:2694-2698.
150. [150] Arber S, Hunter JJ, Ross Jr. J, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997;88:393-403.
151. [151] Edwards JG, Lyons GE, Micales BK, Malhotra A, Factor S, Leinwand LA. Cardiomyopathy in trangenic myf5 mice. Circ Res 1996;78:379-387.
152. [152] Iwase M, Uechi M, Vatner DE, et al. Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Phys 1997;272:H585-H589.
153. [153] Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science 1995;268:1350-1353.
154. [154] Rockman HA, Hamilton R, Rahman NU, et al. Dampened cardiac function in vivo in transgenic mice overexpression GRK5, a G protein-coupled receptor kinase. Circulation 1995;92(Suppl I):240.
155. [155] Hassankhani A, Steinhelper ME, Soonpaa MH, et al. Overexpression of NGF within the heart of transgenic mice causes hyperinnervation, cardiac enlargement, and hyperplasia of ectopic cells. Dev Biol 1995;169:309-321.
156. [156] Reiss K, Cheng W, Ferber A, et al. Overexpression of IGF-1 in the heart is coupled with myocyte proliferation in transgenic mice. Circulation 1995;92(Suppl I):370.
157. [157] Huen DS, Fox A, Kumar P, Searle PF. Dilated heart failure in transgenic mice expression the Epstein-Barr virus nuclear antigen-leader protein. J Gen Virol 1993;74:1381-1391.
158. [158] Chalifour LE, Gomes ML, Wang NS, Mes Masson AM. Polyomavirus large T-antigen expression in heart of transgenic mice causes cardiomyopathy. Oncogene 1990;5:1719-1726.
159. [159] Sussman MA, Welch S, Klevitsky R, Hewett TE, Cambon N. Lethal cardiomyopathy in juvenile mice caused by tropomodulin overexpression. Circulation 1997;98(Suppl I):571.
160. [160] Pinto YM, Ganten D. Animal models of hypertension. Cardiovasc Res this issue.
161. [161] Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-785.
162. [162] Geisterfer-Lowrance AAT, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996;272:731-734.
163. [163] Welikson RE, Vikstrom KL, Factor SM, Weinberger HD, Leinwand LA. Heavy chains lacking the light chain binding domain cause genetically dominant cardiomyopathy in mice. Circulation 1997;96(Suppl I):571.
164. [164] Hunter JJ, Tanaka N, Rockman HA, Ross Jr. J, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995;270:23173-23178.
165. [165] Gottstall KR, Hunter JJ, Tanaka N, et al. Ras dependent pathways induce obstructive hypertrophy in echo-selected trangenic mice. Proc Natl Acad Sci USA 1997;94:4710-4715.
166. [166] Gruver CL, DeMayo F, Goldstein MA, Means AR. Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in trangenic mice. Endocrinology 1993;133:376-388.
167. [167] Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-retransducing receptor component for interleukin 6-related cytokines, cause myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995;92:4862-4866.
168. [168] Milano CA, Dolber PC, Rockman HA, et al. Myocardial expression of a constitutively active α1b-adrenergic receptor in trangenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 1994;91:10109-10113.
169. [169] Graham BH, Waymire KG, Cottrell B, et al. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 1997;16:226-234.
170. [170] Kawai C, Matsumori A, Fujiwara H. Myocarditis and dilated cardiomyopathy. Annu Rev Med 1987;38:221-239.
171. [171] Tanaka A, Matsumori A, Wang W, Sasayama S. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 1994;90:2051-2055.
172. [172] Martino TA, Liu P, Sole MJ. Viral infection and the pathogenesis of dilated cardiomyopathy: time to revisit the virus. Heart Failure 1993;9:218-226.
173. [173] Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J Immunol 1993;151:1682-1690.
174. [174] Huber SA. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strain of mice. Lab Invest 1997;76:691-701.
175. [175] Matsumori A, Kawai C. An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. Circulation 1982;65:1230-1235.
176. [176] Matsumori A, Sasayama S. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy - lessons from animal experiments. Eur Heart J 1995;(Suppl 0):140-143.
177. [177] Hirono S, Islam MO, Nakazawa M, et al. Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics. Circ Res 1997;80:11-20.
178. [178] Sharaf AR, Narula J, Nicol PD, Southern JF, Khaw BA. Cardiac sarcoplasmic reticulum calcium ATPase, an autoimmune antigen in experimental cardiomyopathy. Circulation 1994;89:1217-1228.
179. [179] Schulze K, Schultheiss HP. The role of the ADP/ATP carrier in the pathogenesis of viral heart disease. Eur Heart J 1995;16(Suppl O):64-67.
180. [180] Liu P, Penninger J, Aitken K, Sole M, Mak T. The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Eur Heart J 1995;16(Suppl O):25-27.
181. [181] Aitken K, Penninger J, Mak T, et al. Increased susceptibility to coxsackie viral myocarditis in IRF-1 transgenic knockout mice. Circulation 1994;90(Suppl I):139.
182. [182] Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse tranforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-699.
183. [183] Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor β-1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-774.
184. [184] Jannini JP, Spinale FG. The identification of contributory mechanisms for the development and progression of congestive heart failure in animal models. J Heart Lung Transplant 1996;15:1138-1150.
185. [185] Liu Z, Hilbelink DR, Crockett WB, Gerdes AM. Regional changes in hemodynamics and cardiac myocyte size in rats with aortocaval fistulas. Developing and established hypertrophy . Circ Res 1991;69:52-58.
186. [186] Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Cardiovasc Drugs Ther 1994;8:65-73.
187. [187] Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994;75:105-113.
188. [188] Capasso JM, Li P, Guideri G, et al. Myocardial mechanical, biochemical and structural alterations induced by chronic ethanol ingestion in rats. Circ Res 1992;71:346-356.
189. [189] Wei CM, Clavell AL, Burnett JC. Atrial and pulmonary endothelin mRNA is increased in a canine model of chronic low cardiac output. Am J Physiol 1997;273:R838-844.
190. [190] Magovern JA, Christlieb IY, Badylak SF, Lantz GC, Kao RL. A model of left ventricular dysfunction caused by intracoronary adriamycin. Ann Thorac Surg 1992;53:861-863.
191. [191] Zhang J, Wilke N, Wang Y, et al. Functional and bioenergetic consequences of postinfarction left ventricular remodeling in a new porcine model. MRI and 31 P-MRS study. Circulation 1996;94:1089-1100.
192. 2+-pump ATPase activity in tachycardia heart failure. Cell Calcium 1994;16:349-356.
193. [193] Siri FM, Nordin C, Factor SM, Sonnenblick E, Aronson R. Compensatory hypertrophy and failure in gradual pressure-overloaded guinea pig heart. Am J Physiol 1989;257:H1016-H1024.
194. [194] Tagawa H, Koide M, Sato H, Cooper 4th G. Cytoskeletal role in the contractile dysfunction of cardiocytes from hypertrophied and failing right ventricular myocardium. Proc Assoc Am Physicians 1996;108:218-229.
195. 2+ exchanger in response to cardiac pressure overload. Am J Physiol 1993;265:H1024-H1029.
196. [196] Genao A, Seth K, Schmidt U, Carles M, Gwathmey JK. Dilated cardiomyopathy in turkeys: an animal model for the study of human heart failure. Lab Anim Sci 1996;46:399-404.
197. [197] Eschenhagen T, Diederich M, Kluge SH, et al. Bovine hereditary cardiomyopathy: an animal model of human dilated cardiomyopathy. J Mol Cell Cardiol 1995;27:357-370.
198. [198] Rademaker MT, Charles CJ, Lewis LK, et al. Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. Circulation 1997;96:1983-1990.
199. [199] Rademaker MT, Charles CJ, Espiner EA, et al. Natriuretic peptide responses to acute and chronic ventricular pacing in sheep. Am J Physiol 1996;270:H594-H602.
200. [200] Aoyagi T, Fujii AM, Flanagan MF, et al. Transition from compensated hypertrophy to intrinsic myocardial dysfunction during development of left ventricular pressure-overload hypertrophy in conscious sheep. Systolic dysfunction precedes diastolic dysfunction. Circulation 1993;88:2415-2425.
201. [201] Julian FJ, Morgan DL, Moss RL, Gonzalez M, Dwivedi P. Myocyte growth without physiological impairment in gradually induced rat cardiac hypertrophy. Circ Res 1981;49:1300-1310.
202. [202] Goldblatt H, Lynch J, Hanzak RF, Summerville WW. Studies of experimental hypertension; I. Production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934;59:347-379.
203. [203] Besse S, Robert V, Assayag P, Delcayre C, Swynghedauw B. Nonsynchronous changes in myocardial collagen mRNA and protein during aging: effect of DOCA-salt hypertension. Am J Physiol 1994;267:H2237-2244.
204. [204] Dart Jr. CH, Holloszy JO. Hypertrophied non-failing rat heart; partial biochemical characterization. Circ Res 1969;25:245-253.
205. [205] Bartosova D, Chvapil M, Korecky B, et al. The growth of the muscular and collagenous parts of the rat heart in various forms of cardiomegaly. J Physiol (Lond) 1969;200:285-295.
206. [206] Hickson RC, Hammons GT, Holloszy JO. Development and regression of exercise-induced cardiac hypertrophy in rats. Am J Physiol 1979;236:H268-H272.
207. [207] Rupp H, Jacob R. Response of blood pressure and cardiac myosin polymorphism to swimming training in the spontaneously hypertensive rat. Can J Physiol Pharmacol 1982;60:1098-1103.
208. [208] Koide M, Nagatsu M, Zile MR, et al. Premorbid determinants of left ventricular dysfunction in a novel model gradually induced pressure overload in the adult canine. Circulation 1997;95:1601-1610.
209. 2 consumption in experimental LVH. Am J Physiol 1995;268:H1202-H1207.
210. [210] Dolber PC, Bauman RP, Rembert JC, Greenfield Jr. JC. Regional changes in myocyte structure in model of canine right atrial hypertrophy. Am J Physiol 1994;267:H1279-H1287.
211. [211] Carroll SM, Nimmo LE, Knoepfler PS, White FC, Bloor CM. Gene expression in a swine model of right ventricular hypertrophy: intercellular adhesion molecule, vascular endothelial growth factor and plasminogen activators are upregulated during pressure overload. J Mol Cell Cardiol 1995;27:1427-1441.
212. [212] Do E, Baudet S, Verdys M, et al. Energy metabolism in normal and hypertrophied right ventricle of the ferret heart. J Mol Cell Cardiol 1997;29:1903-1913.
213. 2+ sensitivity in ferret cardiac myocytes with pressure-overload hypertrophy. Am J Physiol 1994;267:H918-H924.
214. [214] Charles CJ, Kaaja RJ, Espiner EA, et al. Natriuretic peptides in sheep with pressure overload left ventricular hypertrophy. Clin Exp Hypertens 1996;18:1051-1071.
215. [215] Hoit BD, Pawloski-Dahm CM, Shao Y, Gabel M, Walsh RA. The effects of a thyroid hormone analog on left ventricular performance and contractile and calcium cycling proteins in the baboon. Proc Assoc Am Physicians 1997;109:136-145.
216. [216] Hoit BD, Shao Y, Gabel M, Walsh RA. Disparate effects of early pressure overload hypertrophy on velocity-dependent and force-dependent indices of ventricular performance in the conscious baboon. Circulation 1995;91:1213-1220.
217. [217] Tweedie D, Henderson CG, Kane KA. Assessment of subrenal banding of the abdominal aorta as a method of inducing cardiac hypertrophy in the guinea pig. Cardioscience 1995;6:115-119.
218. [218] Wiesel P, Mazzolai L, Nussberger J, Pedrazzini T. Hypertension 1997;29:1025-1030.
219. [219] Kaplan ML, Cheslow Y, Vikstrom K, et al. Cardiac adaptations to chronic exercise in mice. Am J Physiol 1994;267:H1167-H1173.
220. [220] Dorn 2nd GW, Robbins J, Ball N, Walsh RA. Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice. Am J Physiol 1994;267:H400-H405.
221. [221] Jackson T, Allard MF, Sreenan CM, et al. The c-myc protooncogene regulates cardiac development in transgenic mice. Mol Cell Biol 1990;10:3709-3716.
222. [222] Hunter JJ, Tanaka N, Rockman HA, Ross J, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995;270:23173-23178.
223. 1-adrenoceptors in transgenic mice. Cardiovasc Res 1993;27:1606-1612.
224. [224] Langheinrich M, Lee MA, Bohm M, et al. The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens 1996;9:506-512.